Author:
Ye Yazoume,Arnold Fred,Noor Abdisalan,Wamukoya Marilyn,Amuasi John,Blay Samuel,Mberu Blessing,Ren Ruilin,Kyobutungi Catherine,Wekesah Frederick,Gatakaa Hellen,Toda Mitsuru,Njogu Julius,Evance Illah,O’Connell Kathryn,Shewchuk Tanya,Thougher Sarah,Mann Andrea,Willey Barbara,Goodman Catherine,Hanson Kara
Publisher
Springer Science and Business Media LLC
Subject
Infectious Diseases,Parasitology
Reference11 articles.
1. Talisuna A, Grewal P, Rwakimari JB, Mukasa S, Jagoe G, Banerji J, et al. Cost is killing patients: subsidising effective antimalarials. Lancet. 2009;374:1224–6.
2. The Global Fund to Fight AIDS, Tuberculosis and Malaria. Affordable Medicines Facility-malaria. Geneva; 2008.
3. Adeyi O, Atun R. Universal access to malaria medicines: innovation in financing and delivery. Lancet. 2010;376:1869–71.
4. Tougher S, ACTwatch Group, Ye Y, Amuasi JH, Kourgueni IA, Thomson R, et al. Effect of the Affordable Medicines Facility-malaria (AMFm) on the availability, price, and market share of quality-assured artemisinin-based combination therapies in seven countries: a before-and-after analysis of outlet survey data. Lancet. 2012;380:1916–26.
5. AMFm Independent Evaluation Team. Independent Evaluation of Phase 1 of the Affordable Medicines Facility-malaria (AMFm): Multi-country Independent Evaluation Report. Calverton: ICF International and London School of Hygiene and Tropical Medicine; 2012.